tiprankstipranks
Trending News
More News >
Eli Lilly And Company (LLY)
:LLY
Advertisement

Eli Lilly & Co (LLY) AI Stock Analysis

Compare
17,725 Followers

Top Page

LLY

Eli Lilly & Co

(NYSE:LLY)

Rating:69Neutral
Price Target:
$835.00
▲(9.01% Upside)
Eli Lilly's overall stock score reflects strong financial performance and a positive outlook from its recent earnings call, driven by significant product contributions and strategic investments. However, the high valuation and mixed technical signals suggest caution. The company's high leverage and potential regulatory hurdles also warrant careful monitoring.
Positive Factors
Clinical Trial Success
Mounjaro was associated with a 16% lower rate of all-cause death compared to Trulicity, suggesting more comprehensive health benefits.
Financial Performance
The overall setup for LLY shares looks very favorable due to expected strong 2Q results and high probability clinical catalysts.
Growth Potential
There is room for upside in LLY stock due to persistent strength in Zepbound and Mounjaro growth from their more competitive efficacy and safety profile compared to semaglutide.
Negative Factors
Clinical Trial Challenges
Regarding safety, 13.3% of patients on Mounjaro discontinued treatment due to side effects, slightly higher than the 10.2% with Trulicity.
Market Sentiment
The recent weakness in LLY shares following Novo’s guidance cut was viewed as unjustified.
Statistical Significance
Mounjaro achieved non-inferiority to Trulicity, with an 8% reduction in risk of MACE vs Trulicity, however falling short of statistical significance, with a p-value of only 0.086.

Eli Lilly & Co (LLY) vs. SPDR S&P 500 ETF (SPY)

Eli Lilly & Co Business Overview & Revenue Model

Company DescriptionEli Lilly & Co (LLY) is a global pharmaceutical company headquartered in Indianapolis, Indiana. The company focuses on the discovery, development, manufacturing, and marketing of pharmaceutical products. Eli Lilly is renowned for its work in the fields of endocrinology, oncology, neuroscience, and immunology, with prominent products including insulin, cancer therapies, and treatments for mental health disorders.
How the Company Makes MoneyEli Lilly & Co generates revenue primarily through the sale of its pharmaceutical products. Key revenue streams include sales of diabetes medications, such as Humalog and Trulicity, cancer treatments like Verzenio, and immunology drugs such as Taltz. The company invests heavily in research and development to bring new drugs to market, which can lead to significant revenue growth from successful product launches. Additionally, strategic partnerships and collaborations with other biotech firms and research institutions help Eli Lilly expand its product pipeline and market reach. The company's earnings are also influenced by patent protections, regulatory approvals, and market exclusivity periods, which allow them to capitalize on new innovations.

Eli Lilly & Co Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Shows revenue distribution across different business units or product lines, highlighting which areas drive growth and which may need strategic adjustments.
Chart InsightsEli Lilly's Diabetes segment is experiencing significant growth, driven by the success of Mounjaro and Zepbound, which are pivotal in the company's 45% revenue increase. This surge is supported by strong sales and market leadership in anti-obesity prescriptions. However, challenges such as regulatory hurdles and market dynamics in the obesity segment could impact future performance. The company's strategic investments in manufacturing and pipeline expansion, including the success of the Orforglipron trial, suggest a cautiously optimistic outlook despite these challenges.
Data provided by:Main Street Data

Eli Lilly & Co Earnings Call Summary

Earnings Call Date:May 01, 2025
(Q1-2025)
|
% Change Since: -14.62%|
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Neutral
The earnings call presented strong financial growth driven by key products, successful trial results, and significant investments in manufacturing. However, challenges remain with regulatory hurdles, potential tariff impacts, and market dynamics in the obesity segment. The balance of positive revenue growth and strategic investments against these challenges suggests a cautiously optimistic outlook.
Q1-2025 Updates
Positive Updates
Strong Revenue Growth
Revenue grew 45% compared to Q1 of 2024, driven by key products like Mounjaro and Zepbound, which contributed over $4 billion in growth and accounted for $7.5 billion of the company's revenue.
Phase 3 Orforglipron Trial Success
Orforglipron achieved significant results in its Phase 3 trial for Type 2 diabetes, with hemoglobin A1c reductions of 1.3% to 1.6% and weight loss of approximately 16 pounds or 7.9% body weight at the highest dose.
Manufacturing Investment Expansion
Lilly announced over $50 billion in new U.S. manufacturing investments since 2020, including plans to build four new facilities, three of which will be active pharmaceutical ingredient facilities.
Strong Performance of Mounjaro and Zepbound
Mounjaro sales were $3.8 billion, more than double the same quarter last year, and Zepbound sales increased by $1.8 billion to $2.3 billion, making it the U.S. market leader in anti-obesity prescriptions.
Strong Financial Performance Metrics
Gross margin increased to 83.5% in Q1, and the non-GAAP performance margin was 42.6%, an increase of over 11 percentage points from Q1 2024.
Negative Updates
U.S. Regulatory Challenges for Heart Failure Indication
Lilly withdrew its U.S. application for heart failure with preserved ejection fraction indication for Tirzepatide due to FDA indicating the need for an additional confirmatory clinical trial.
Potential Impact of Trade Tariffs
While current tariffs do not materially change Lilly's 2025 financial outlook, expansion of tariffs in other geographies could negatively affect the company and the broader industry.
Price Declines in Key Markets
In the U.S., there was a 7% price decline, while in Europe, constant currency revenue growth was partially offset by a 7% decline in price.
CVS Formulary Change Concerns
CVS announced a formulary change favoring Wegovy over Zepbound, raising investor concerns about the impact on market share and pricing dynamics in the obesity market.
Company Guidance
During the Q1 2025 earnings call, Eli Lilly & Company reported a robust financial performance with a 45% increase in revenue compared to Q1 2024, driven by key products like Mounjaro, Zepbound, and Verzenio. The company's gross margin was 83.5%, with marketing expenses increasing by 26% and R&D expenses by 8%. Lilly achieved several pipeline milestones, including the approval of Omvoh in the U.S., EU, and Japan. They also announced significant U.S. manufacturing investments exceeding $50 billion since 2020. Despite the impact of acquired IPR&D charges reducing earnings per share by $1.72, the company delivered an EPS of $3.34. Looking ahead, Lilly anticipates further clinical trial readouts for orforglipron and potential regulatory submissions for obesity treatments by year-end 2025, while maintaining a focus on expanding their product pipeline and manufacturing capabilities.

Eli Lilly & Co Financial Statement Overview

Summary
Eli Lilly & Co shows strong financial health with impressive revenue and profit growth, robust margins, and high ROE. The company effectively manages cash flows with improvements in free cash flow. However, high leverage and a low equity ratio suggest careful monitoring of financial obligations.
Income Statement
85
Very Positive
Eli Lilly & Co has demonstrated strong revenue growth with a significant increase in Total Revenue from $45.04B to $49.00B TTM (Trailing-Twelve-Months), representing a growth rate of 8.77%. Gross Profit Margin is robust at 81.69%, and Net Profit Margin has improved to 22.67%. The EBIT Margin is healthy at 41.17%, and EBITDA Margin stands at 36.35%. Overall, the income statement reflects strong profitability and growth trends, positioning the company well within its industry.
Balance Sheet
68
Positive
The balance sheet shows a moderate Debt-to-Equity Ratio of 2.44, indicating a higher leverage position which poses some risk. However, the Return on Equity (ROE) is impressive at 70.48%, reflecting strong profitability relative to shareholder equity. The Equity Ratio is relatively low at 17.64%, suggesting limited equity financing. While profitability metrics are strong, the high leverage warrants cautious monitoring.
Cash Flow
75
Positive
Free Cash Flow has grown significantly to $1.21B TTM, a notable improvement from previous periods. The Operating Cash Flow to Net Income Ratio is 0.84, indicating efficient cash generation from operations. Free Cash Flow to Net Income Ratio is 0.11, highlighting room for improvement in converting income to free cash. Overall, cash flow metrics are solid, with positive growth trends in free cash flow.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue45.04B34.12B28.54B28.32B24.54B
Gross Profit36.62B27.04B21.91B21.01B19.06B
EBITDA15.23B8.57B8.66B8.04B8.91B
Net Income10.59B5.24B6.24B5.58B6.19B
Balance Sheet
Total Assets78.71B64.01B49.49B48.81B46.63B
Cash, Cash Equivalents and Short-Term Investments3.42B2.93B2.21B3.91B3.68B
Total Debt33.64B25.23B16.24B16.88B16.60B
Total Liabilities64.44B53.14B38.71B39.65B40.81B
Stockholders Equity14.19B10.77B10.65B8.98B5.64B
Cash Flow
Free Cash Flow414.30M-3.15B4.60B5.39B4.47B
Operating Cash Flow8.82B4.24B7.59B7.37B6.50B
Investing Cash Flow-9.30B-7.15B-3.76B-2.87B-2.26B
Financing Cash Flow1.23B3.50B-5.41B-4.13B-3.14B

Eli Lilly & Co Technical Analysis

Technical Analysis Sentiment
Negative
Last Price765.95
Price Trends
50DMA
775.03
Negative
100DMA
783.74
Negative
200DMA
801.10
Negative
Market Momentum
MACD
-4.12
Positive
RSI
46.78
Neutral
STOCH
35.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LLY, the sentiment is Negative. The current price of 765.95 is below the 20-day moving average (MA) of 779.44, below the 50-day MA of 775.03, and below the 200-day MA of 801.10, indicating a bearish trend. The MACD of -4.12 indicates Positive momentum. The RSI at 46.78 is Neutral, neither overbought nor oversold. The STOCH value of 35.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LLY.

Eli Lilly & Co Risk Analysis

Eli Lilly & Co disclosed 16 risk factors in its most recent earnings report. Eli Lilly & Co reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Eli Lilly & Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$231.36B27.7919.76%2.08%15.17%29.15%
79
Outperform
$202.87B12.4635.44%4.04%2.01%
78
Outperform
$411.20B18.2630.21%2.94%4.69%34.88%
76
Outperform
$212.12B13.9875.95%3.34%22.74%16.36%
73
Outperform
$350.75B94.49112.90%3.31%6.05%
69
Neutral
$725.92B63.7077.73%0.73%36.38%80.73%
51
Neutral
$7.39B0.42-62.86%2.37%15.61%-1.93%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
LLY
Eli Lilly & Co
765.95
-73.61
-8.77%
AZN
AstraZeneca
74.48
-5.76
-7.18%
JNJ
Johnson & Johnson
170.74
15.58
10.04%
MRK
Merck & Company
80.79
-29.41
-26.69%
NVO
Novo Nordisk
47.22
-79.16
-62.64%
ABBV
AbbVie
198.55
14.73
8.01%

Eli Lilly & Co Corporate Events

Executive/Board ChangesShareholder Meetings
Eli Lilly & Co Shareholders Vote on Key Issues
Neutral
May 8, 2025

At the 2025 Annual Meeting held on May 5, Eli Lilly & Co shareholders voted on several key issues. Four directors were elected for three-year terms, executive compensation was approved, and Ernst & Young LLP was ratified as the independent auditor for 2025. However, proposals to amend the Articles of Incorporation to eliminate the classified board structure and supermajority voting provisions did not pass.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 30, 2025